Organon & Co reports results for the quarter ended June 30 - Earnings Summary

Organon & Co.

03/08/2026 14:31

Organon & Co OGN.N reported quarterly adjusted earnings of 85 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $1.00.  The mean expectation of eight analysts for the quarter was for earnings of 92 cents per share. Wall Street expected results to range from 82 cents to $1.07 per share.
Revenue fell 2.3% to $1.56 billion from a year ago; analysts expected $1.57 billion. 
Organon & Co's reported EPS for the quarter was 40 cents​.
The company reported quarterly net income of $108 million.
Organon & Co shares had risen by 0.1% this quarter and gained 89.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Organon & Co is $9.00, about 50.6% below its last closing price of $13.55
This summary was machine generated from LSEG data August 3 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.92
0.85
Missed
Mar. 31 2026 
0.83
0.71
Missed
Dec. 31 2025 
0.73
0.63
Missed
Sep. 30 2025 
0.94
1.01
Beat